New insider activity at Apimeds Pharmaceuticals US, Inc. ( (APUS) ) has taken place on May 15, 2025.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
In a notable series of transactions, significant shareholder Inscobee Inc. has acquired 500,000 shares of Apimeds Pharmaceuticals US, Inc., amounting to a substantial investment of $2,000,000. Additionally, Director Jakap Koo has purchased 28,500 shares of the same company, with this acquisition valued at $56,715.
Recent Updates on APUS stock
In the last 24 hours, Apimeds Pharmaceuticals US, Inc. (APUS) has seen significant developments following its initial public offering (IPO) on May 12, 2025. The company successfully raised $13.5 million by offering 3,375,000 shares at $4.00 each. The proceeds are earmarked for advancing their clinical trials, including a Phase III trial for knee osteoarthritis and a study in multiple sclerosis, as well as for manufacturing and general working capital needs. The IPO also involved converting convertible promissory notes into common stock, which has strengthened the company’s financial structure. These strategic financial moves are likely influencing analysts’ price target considerations as they reflect the company’s commitment to advancing its clinical pipeline and enhancing its financial stability.
More about Apimeds Pharmaceuticals US, Inc.
YTD Price Performance: -20.45%
Average Trading Volume: 841,128